Efficacy of low-density lipoprotein apheresis in patients with peripheral arterial occlusive disease undergoing hemodialysis treatment.

Efficacy of low-density lipoprotein apheresis in patients with peripheral arterial occlusive disease undergoing hemodialysis treatment. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Efficacy of low-density lipoprotein apheresis in patients with peripheral arterial occlusive disease undergoing hemodialysis treatment. Abstract Text:

Satoshi Morimoto,Yutaka Yano,Kei Maki,Katsunori Sawada,Toshiji Iwasaka,Satoshi Morimoto,Yutaka Yano,Kei Maki,Katsunori Sawada,Toshiji Iwasaka,

BACKGROUND: Low-density lipoprotein (LDL) apheresis is effective in the treatment of peripheral arterial occlusive disease (PAOD). In the present study, we attempted to determine whether LDL apheresis is effective even for PAOD patients undergoing hemodialysis, who tend to be refractory to any treatment, and if so, to determine the mechanism of its efficacy. METHODS: Serum levels of lipids and vascular growth factors, leg symptom, and endothelium-dependent vasodilation were investigated before and after 10 sessions of LDL apheresis in 11 PAOD patients undergoing hemodialysis. RESULTS: Serum levels of total cholesterol, LDL cholesterol, and triglyceride exhibited drastic reduction, which completely disappeared 4 weeks after the final apheresis. Resting leg pain was improved in 6 cases even 4 weeks after final apheresis. Endothelium-dependent vasodilation was significantly increased 4 weeks after final apheresis (1.6 +/- 0.6 to 4.7 +/- 1.0%, p < 0.05). Levels of vascular growth factors, hepatocyte growth factor and vascular endothelial growth factor were not changed during treatment. CONCLUSIONS: These findings suggested that LDL apheresis is effective even in PAOD patients undergoing hemodialysis. Our findings suggest that its mechanisms of efficacy include improvement of vascular endothelial dysfunction, in addition to drastic but acute reduction of lipid levels. Since PAOD patients undergoing hemodialysis tend to be resistant to any treatment and are at high risk for lower-extremity amputation, LDL apheresis could be a useful strategy for treatment of them.

Efficacy of low-density lipoprotein apheresis in patients with peripheral arterial occlusive disease undergoing hemodialysis treatment. Publishing Authors By Initials

S Morimoto,Y Yano,K Maki,K Sawada,T Iwasaka,S Morimoto,Y Yano,K Maki,K Sawada,T Iwasaka,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Efficacy of low-density lipoprotein apheresis in patients with peripheral arterial occlusive disease undergoing hemodialysis treatment. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: American journal of nephrology

VOLUME: 27

Page Numbers: 643-8

Journal Abbreviation: Am. J. Nephrol.

ISSN: 1421-9670

DAY: 18

MONTH: 09

YEAR: 2007

Efficacy of low-density lipoprotein apheresis in patients with peripheral arterial occlusive disease undergoing hemodialysis treatment. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8109361

Efficacy of low-density lipoprotein apheresis in patients with peripheral arterial occlusive disease undergoing hemodialysis treatment. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Efficacy of low-density lipoprotein apheresis in patients with peripheral arterial occlusive disease undergoing hemodialysis treatment. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Efficacy of low-density lipoprotein apheresis in patients with peripheral arterial occlusive disease undergoing hemodialysis treatment.

AFFILIATION: Department of Internal Medicine, Ohmihachiman City Hospital, Osaka, Japan. morimots@hirakata.kmu.ac.jp

Country: Switzerland

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Am J Nephrol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Efficacy of low-density lipoprotein apheresis in patients with peripheral arterial occlusive disease undergoing hemodialysis treatment Related Publications

• Adiponectin incompletely prevent MCP-1-dependent restenosis after percutaneous coronary intervention in patients with coronary artery disease.
• Angiotensin II type 1 receptor blocker preserves tolerance to ischemia-reperfusion injury in Dahl salt-sensitive rat heart.
• Antiproliferative effects of the major tea polyphenol, (-)-epigallocatechin gallate and retinoic acid in cervical adenocarcinoma.
• Correlation between adiponectin and reduction of cell adhesion molecules after pitavastatin treatment in hyperlipidemic patients with type 2 diabetes mellitus.
• Differences in functional roles between activated platelets and platelet-derived microparticles.
• Effects of pitavastatin on adiponectin in patients with hyperlipidemia.
• Efficacy of low-density lipoprotein apheresis in patients with peripheral arterial occlusive disease undergoing hemodialysis treatment.
• Limitation of antiplatelet therapy after percutaneous coronary intervention.
• Management of patients with recurrent nephrosis and intractable edema by intraperitoneal instillation of icodextrin solution.
• N-acetylcysteine abolishes the protective effect of losartan against left ventricular remodeling in cardiomyopathy hamster.
• Nicorandil suppressed myocardial injury after percutaneous coronary intervention.
• Non-invasive detection of ischemic left ventricular dysfunction using rest gated SPECT: expectation of simultaneous evaluation of both myocardial perfusion and wall motion abnormality.
• Prognosis of subjects with brugada-type electrocardiogram in a population of middle-aged Japanese diagnosed during a health examination.
• Renal and vascular protective effects of cilnidipine in patients with essential hypertension.
• Three-dimensional echocardiographic assessment of left ventricular function in takotsubo cardiomyopathy.
• Uterine artery embolization followed by dilation and curettage for cervical pregnancy.